Abstract: The present disclosure describes a computerized system for a method that includes: accessing brain images of a patient, e.g., a patient who has been diagnosed with a psychotic disorder, or at high risk for developing the psychotic disorder, wherein the brain images comprise a first set of images depicting a brain structure of the patient and a second set of images encoding a brain function of the patient; generating masks based on morphing a symptom region of an atlas to the first set of images, wherein the atlas is based on a cohort of participants with the psychotic disorder; identifying treatment regions based on applying the one or more masks to the second set of images, wherein the treatment regions are specific to the patient and the symptom; and causing at least one transcranial magnetic stimulation (TMS) therapy session targeting the one or more treatment regions to be administered.

Abstract: High levels of D-serine occur in mammalian brain, where it appears to be an endogenous ligand of the “glycine site” of NMDA receptors. We have purified from rat brain a soluble enzyme that catalyzes the direct racemization of L-serine to D-serine. Purified serine racemase has a molecular weight of 37 kDa and requires pyridoxal 5?-phosphate for its activity. The enzyme is highly selective toward L-serine, failing to racemize any other amino acid tested. We have also identified polynucleotide sequences that encode mammalian, including human, serine racemase. Compounds that modulate the activity of mammalian serine racemase are useful for treating conditions and diseases that involve overstimulation of NMDA receptors, such as stroke and various neurodegenerative diseases.